Health News Releases

  • Today November 18
November 17, 15:50
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatolog
November 16, 13:40
Stealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune Disease
Third Rock Ventures and Parse Biosciences today announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs) using Parse Biosciences’ GigaLab platform. The
Bernard Tannoury, President of Benta SAS, and Sohail Zaidi, CEO of Ananda Scientific Inc., signing t
November 16, 13:25
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understandin
November 14, 15:10
Galderma Completes Successful Placement of CHF 175 Million Bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play de
November 13, 14:50
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma
The U.S. Food and Drug Administration (FDA) has approved the Promega (https://bit.ly/4nUmP66) OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatelli
November 13, 10:55
InterSystems Launches HealthShare AI Assistant to Optimize Data Retrieval and Clinical Engagement with Conversational Intelligence
InterSystems (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.intersystems.com%2F&esheet=54356186&newsitemid=20251112864064&lan=en-US&anchor=InterSystems&index=1&md5=a79330a679c0
Qorium is successfully producing sustainable real leather
November 12, 16:25
Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation
Qorium, the Dutch biotechnology company pioneering cultivated leather, today announced it has secured a €22 million investment from Invest-NL and LIOF alongside existing investors Brightlands Venture
November 12, 10:40
Prokarium Appoints Ibs Mahmood as Chief Executive Officer
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kri
Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to h
November 11, 16:20
Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms
Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexL
November 10, 15:40
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of
November 10, 10:15
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered
November 09, 09:50
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54353741&newsitemid=20251107689017&lan=en-US&anchor=TSE%3A4
NJ Bio, Inc. now offers translational research services after completing asset purchase and full int
November 07, 11:30
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Res
Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncolog
November 07, 10:10
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreeme
November 07, 09:50
Merz Aesthetics® Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only FDA-Cleared Ultrasound With Real-Time Visualization
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the U.S. Food and Drug Administration (FDA) clearance of Ultherapy PRIME to improve the appearance of skin l
November 05, 16:10
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for augment
November 05, 11:50
Merz Aesthetics® Introduces New BELOTERO® Syringe Offering Greater Precision, Comfort and Ease of Use
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®. The new syringe i
November 04, 08:39
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54348492&newsitemid=20251030478402&lan=en-US&anchor=TSE%3A4
Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings,
November 03, 11:44
Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary
Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Sams
October 31, 10:40
Novotech Maps Global Growth in Radiopharmaceutical Trials
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, today released a new white paper detailing the rapid rise of therapeutic radiopharmaceutical research a
October 31, 10:15
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China
October 30, 16:51
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54345580&newsitemid=20251029831616&lan=en-US&anc
October 30, 16:30
SS&C Introduces AI Agents to Simplify Financial Services and Healthcare Operations
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2025-Enterprise-Press-Release-1025&utm_medium=pressrelease&utm_source=prnews&utm_content=SSNC-AI-Agents) (Nasdaq: SSNC) today
October 30, 16:20
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics
Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual,
ONEWAYLAB team member demonstrating the company’s flagship device to visitors at the Beautyworld Mid
October 30, 13:52
ONEWAYLAB Expands Global Presence with Cutting-Edge Beauty Tech at Beautyworld Middle East 2025
ONEWAYLAB Co., Ltd. announced its participation in Beautyworld Middle East 2025, one of the world’s leading exhibitions for the beauty and wellness industries, held in Dubai. Certified as an offici
25 per page50 per page75 per page100 per page